Novartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
Another Big Pharma is retreating from the antibiotics field.
Novartis today says its early-stage research group at NIBR is dropping antibacterial and antiviral research programs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
